Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance‐associated substitutions in naïve patients from Argentina
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Medical Virology"
DOI: 10.1002/jmv.25536
Abstract: Direct acting antiviral (DAA) therapy against hepatitis C virus (HCV) increases sustained virologic response rates. Nevertheless, drug resistance has occasionally been associated with failure to DAA. However, the information about the prevalence of NS5A and… read more here.
Keywords: prevalence ns5a; ns5a ns5b; treatment; rass ... See more keywords
Exploring NS3/4A, NS5A and NS5B proteins to design conserved subunit multi-epitope vaccine against HCV utilizing immunoinformatics approaches
Sign Up to like & getrecommendations! Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-34254-5
Abstract: Hepatitis C virus (HCV) vaccines, designed to augment specific T-cell responses, have been designated as an important aspect of effective antiviral treatment. However, despite the current satisfactory progress of these vaccines, extensive past efforts largely… read more here.
Keywords: ns5a ns5b; hcv; vaccine hcv; immunoinformatics approaches ... See more keywords
Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients
Sign Up to like & getrecommendations! Published in 2018 at "Disease Markers"
DOI: 10.1155/2018/2514901
Abstract: Hepatitis C Virus (HCV) infection treatment has dramatically changed with the advent of direct-acting antiviral agents (DAAs). However, the efficacy of DAAs can be attenuated by the presence of resistance-associated substitutions (RASs) before and after… read more here.
Keywords: ns5a ns5b; treatment; infected patients; resistance ... See more keywords